Press-release for stocks in the consumer non-durables sector related to disease

| -25.44% | O: -0.59% H: 0.27% C: -1.83%
PPRUY | News | $34.9595 3.46% -0.11% 390K

| -24.12% | O: -1.85% H: 0.2% C: -0.07%
PCVX | $60.3 -0.95% -1.05% 700K

| -15.91% | O: 0.2% H: 0.18% C: -0.42%
STRO | $3.47 -6.72% -7.2% 730K

| -29.9% | O: 0.2% H: 1.81% C: -3.43%
vax-24 disease pneumococcal study

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
PPRUF | News | $345.01 1.47% 37.56% 1.6K

| -16.86% | O: 0.92% H: 0.76% C: -1.38%
PPRUY | News | $34.9595 3.46% -0.11% 390K

| -16.02% | O: -0.55% H: 1.4% C: 1.28%
PCVX | $60.3 -0.95% -1.05% 700K

| -6.24% | O: 0.26% H: 6.59% C: 6.23%
STRO | $3.47 -6.72% -7.2% 730K

| -26.17% | O: -0.43% H: 6.84% C: 6.62%
vax-31 disease pneumococcal study

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-11-09 (Crawled : 13:30) - globenewswire.com
PPRUF | News | $345.01 1.47% 37.56% 1.6K

| -20.73% | O: -1.41% H: 1.77% C: -1.32%
PPRUY | News | $34.9595 3.46% -0.11% 390K

| -18.83% | O: 1.28% H: 0.21% C: -1.4%
PCVX | $60.3 -0.95% -1.05% 700K

| 19.17% | O: 0.59% H: 0.63% C: -5.62%
STRO | $3.47 -6.72% -7.2% 730K

| 42.8% | O: 4.12% H: 0.0% C: -11.07%
vax-31 disease pneumococcal study

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-10-19 (Crawled : 12:30) - globenewswire.com
PPRUF | News | $345.01 1.47% 37.56% 1.6K

| -21.27% | O: -0.57% H: 1.09% C: 0.98%
PPRUY | News | $34.9595 3.46% -0.11% 390K

| -18.36% | O: 1.4% H: 0.53% C: -0.81%
PCVX | $60.3 -0.95% -1.05% 700K

| 31.0% | O: 0.24% H: 2.54% C: 0.78%
STRO | $3.47 -6.72% -7.2% 730K

| -1.42% | O: -0.28% H: 0.0% C: -6.27%
vax-31 fda drug disease pneumococcal clearance application

United States Leads Global Single Use-Disposable Endoscopes Market to 2030: Adoption of Innovations and Chronic Disease Prevalence
Published: 2023-08-31 (Crawled : 23:00) - prnewswire.com
MDT | $80.38 -1.12% -0.03% 5M

| -2.58% | O: -0.54% H: 0.0% C: 0.0%
K S | $58.75 1.05% 0.0% 2.3M

| -4.28% | O: -0.43% H: 0.54% C: -2.0%
JNJ | News | $148.53 -0.69% 0.18% 7.5M

| -8.37% | O: -0.11% H: 0.0% C: 0.0%
BSX | $72.91 5.68% 0.0% 13M

| 35.17% | O: 0.59% H: 0.0% C: -1.18%
disease global market

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-07-11 (Crawled : 12:20) - globenewswire.com
PPRUF | News | $345.01 1.47% 37.56% 1.6K

| -34.65% | O: 3.26% H: 0.0% C: -0.57%
PPRUY | News | $34.9595 3.46% -0.11% 390K

| -34.05% | O: 1.02% H: 0.9% C: 0.75%
PCVX | $60.3 -0.95% -1.05% 700K

| 26.65% | O: -2.77% H: 2.2% C: 0.65%
STRO | $3.47 -6.72% -7.2% 730K

| -26.95% | O: -1.47% H: 1.71% C: 0.64%
vax-24 disease pneumococcal ongoing study

Global Insect Repellent Active Ingredients Market Report 2023: Rise in Vector-Borne Disease Occurrence Drives Growth
Published: 2023-06-22 (Crawled : 00:00) - prnewswire.com
RBGPF | News | $53.94 3.53% 6.46% 3.4K

| -30.73% | O: 0.12% H: 0.56% C: 0.56%
RBGLY | News | $10.98 2.0% -2.05% 860K

| -29.53% | O: 0.13% H: 0.46% C: 0.38%
disease active report global growth market

Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-03-30 (Crawled : 15:00) - biospace.com/
PPRUF | News | $345.01 1.47% 37.56% 1.6K

| -44.94% | O: 2.52% H: 2.74% C: 2.74%
PPRUY | News | $34.9595 3.46% -0.11% 390K

| -44.88% | O: 1.88% H: 1.04% C: 0.57%
PCVX | $60.3 -0.95% -1.05% 700K

| 63.64% | O: -0.52% H: 0.55% C: -1.06%
STRO | $3.47 -6.72% -7.2% 730K

| -27.25% | O: -1.05% H: 2.86% C: -5.08%
vax-24 disease pneumococcal study phase 2

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
PPRUF | News | $345.01 1.47% 37.56% 1.6K

| -45.94% | O: -3.64% H: 3.09% C: 1.33%
PPRUY | News | $34.9595 3.46% -0.11% 390K

| -44.88% | O: -1.68% H: 1.12% C: -0.58%
PCVX | $60.3 -0.95% -1.05% 700K

| 36.36% | O: -0.93% H: 1.96% C: 0.55%
STRO | $3.47 -6.72% -7.2% 730K

| -44.21% | O: -1.13% H: 5.37% C: -0.98%
vax-24 fda clearance drug disease application pneumococcal

Global Probiotics Business Market Report 2023: Market to Reach $91.7 Billion by 2030 - Rising Focus on Disease Prevention than Treatment and Probiotics' Potential
Published: 2023-02-03 (Crawled : 17:00) - prnewswire.com
GPDNF | $63.48 -1.2% -13.04% 25K

| 16.61% | O: 1.73% H: 0.0% C: 0.0%
DANOY | $12.76 -0.08% 0.08% 280K

| 16.09% | O: -0.36% H: 0.36% C: -0.36%
GIS 4 | $71.61 1.12% 0.55% 3.6M

| -5.65% | O: 0.8% H: 0.04% C: -1.35%
treatment global disease report potential market

Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-01-05 (Crawled : 15:00) - biospace.com/
PPRUF | News | $345.01 1.47% 37.56% 1.6K

| -35.35% | O: 1.3% H: 2.07% C: 1.45%
PPRUY | News | $34.9595 3.46% -0.11% 390K

| -35.51% | O: 0.44% H: 0.55% C: -0.17%
PCVX | $60.3 -0.95% -1.05% 700K

| 28.68% | O: -0.13% H: 0.45% C: -1.58%
STRO | $3.47 -6.72% -7.2% 730K

| -57.16% | O: -0.86% H: 7.35% C: 5.23%
vax-24 fda designation disease granted therapy pneumococcal

Non-steroidal Anti-inflammatory Drugs Market Research Report by Disease Indication, Drugs, Route of Administration, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-07 (Crawled : 16:00) - prnewswire.com
RBGPF | News | $53.94 3.53% 6.46% 3.4K

| -23.78% | O: 0.06% H: 3.15% C: 0.15%
GLAXF | News | $19.54 -3.77% -14.18% 170

| 5.31% | O: 0.74% H: 0.0% C: -6.74%
SNYNF | News | $94.0 -0.27% -2.18% 310

| -3.17% | O: 1.62% H: 0.0% C: -4.28%
AZNCF | News | $135.35 -3.53% -4.19% 400

| -1.02% | O: -0.56% H: 0.61% C: 0.01%
RBGLY | News | $10.98 2.0% -2.05% 860K

| -24.72% | O: 0.51% H: 0.48% C: -0.14%
VTRS | News A | $11.55 1.67% 1.65% 4.4M

| 5.67% | O: 0.0% H: 0.55% C: -0.27%
ZTS | $150.88 0.88% 0.68% 3.2M

| -1.42% | O: -0.06% H: 0.54% C: -1.77%
PRGO | $31.23 2.43% 0.0% 960K

| -1.58% | O: -0.09% H: 0.47% C: -0.28%
GSK | News | $40.86 -0.92% 1.25% 1.6M

| 7.75% | O: -0.98% H: 0.24% C: -1.78%
LLY | News | $732.2 -1.81% -0.84% 1.7M

| 104.11% | O: 0.21% H: 1.6% C: 0.72%
SNY | News | $46.61 -2.27% -2.21% 1.6M

| 5.15% | O: 5.18% H: 0.0% C: 0.0%
AZN | News | $71.2 0.49% 0.46% 5.4M

| 3.85% | O: 0.45% H: 0.64% C: -0.03%
covid-19 research global disease report impact distribution market

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Published: 2022-10-24 (Crawled : 11:00) - biospace.com/
PPRUF | News | $345.01 1.47% 37.56% 1.6K

| -22.33% | O: 0.55% H: 3.41% C: -0.9%
PPRUY | News | $34.9595 3.46% -0.11% 390K

| -22.64% | O: -0.01% H: 0.83% C: -0.01%
PCVX | $60.3 -0.95% -1.05% 700K

| 193.0% | O: 70.8% H: 2.7% C: -6.12%
STRO | $3.47 -6.72% -7.2% 730K

| -38.48% | O: 0.71% H: 14.96% C: 13.91%
candidate disease topline vaccine positive study pneumococcal

Cleanroom Consumables Market to Attract Profitable Prospects with Rise in Prevalence of Infectious Diseases, Says TMR Study
Published: 2022-05-03 (Crawled : 04:00) - prnewswire.com
KMB | $137.78 1.28% 0.32% 2.8M

| -1.28% | O: -2.16% H: 1.58% C: 0.54%
profitable market disease

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Published: 2022-02-23 (Crawled : 22:00) - globenewswire.com
PPRUF | News | $345.01 1.47% 37.56% 1.6K

| -53.37% | O: -8.77% H: 6.66% C: 5.47%
PPRUY | News | $34.9595 3.46% -0.11% 390K

| -51.75% | O: -5.49% H: 3.87% C: 3.65%
PCVX | $60.3 -0.95% -1.05% 700K

| 197.92% | O: -8.4% H: 22.28% C: 21.9%
STRO | $3.47 -6.72% -7.2% 730K

| -57.94% | O: -1.09% H: 8.21% C: 8.09%
vax-24 disease phase 1 pneumococcal

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
Published: 2022-01-06 (Crawled : 15:00) - biospace.com/
PPRUF | News | $345.01 1.47% 37.56% 1.6K

| -57.73% | O: 2.64% H: 0.0% C: -0.39%
PPRUY | News | $34.9595 3.46% -0.11% 390K

| -57.66% | O: -0.99% H: 0.0% C: -1.16%
PCVX | $60.3 -0.95% -1.05% 700K

| 152.2% | O: 4.14% H: 2.57% C: -1.0%
STRO | $3.47 -6.72% -7.2% 730K